ELI LILLY AND COMPANY Deferred Income Tax Assets, Net
ELI LILLY AND COMPANY (LLY) had Deferred Income Tax Assets, Net of $10.03 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-08-05
- 2026-06-30: Deferred Income Tax Assets, Net $10.03B.
- 2026-03-31: Deferred Income Tax Assets, Net $11.35B.
- 2025-12-31: Deferred Income Tax Assets, Net $9.96B.
- 2025-09-30: Deferred Income Tax Assets, Net $8.96B.
| Period end | Deferred Income Tax Assets, Net | Deferred Income Tax Assets, Net as first filed |
|---|---|---|
| 2026-06-30 | $10.03B 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $11.35B 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $9.96B 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $8.96B 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $9.43B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $8.57B 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $8.00B 10-K · filed 2026-02-12 | $8.00B 10-K · filed 2025-02-19 |
| 2024-09-30 | $7.39B 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $6.66B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $5.63B 10-Q · filed 2024-04-30 | |
| 2023-12-31 | $5.48B 10-K · filed 2025-02-19 | |
| 2023-09-30 | $4.57B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $3.81B 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $3.41B 10-Q · filed 2023-04-27 | |
| 2022-12-31 | $2.79B 10-K · filed 2024-02-21 | |
| 2022-09-30 | $2.38B 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $2.37B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $2.46B 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $2.49B 10-K · filed 2023-02-22 | |
| 2021-09-30 | $2.63B 10-Q · filed 2021-10-27 | |
| 2021-06-30 | $2.67B 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $2.65B 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $2.83B 10-K · filed 2022-02-23 | |
| 2020-09-30 | $2.56B 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $2.48B 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $2.47B 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $2.57B 10-K · filed 2021-02-17 | |
| 2019-09-30 | $2.41B 10-Q · filed 2019-10-25 | |
| 2019-06-30 | $2.51B 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $2.51B 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $2.61B 10-K · filed 2020-02-19 | $2.66B 10-K · filed 2019-02-19 |
| 2017-12-31 | $1.22B 8-K · filed 2019-10-24 | $1.17B 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |